| [1] |
GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 [J]. Lancet, 2020, 395(10225): 709-733.
|
| [2] |
Heerspink HJ, Desai M, Jardine M, et al. Canagliflozin slows progression of renal function decline independently of glycemic effects [J]. J Am Soc Nephrol, 2017, 28(1): 368-375.
|
| [3] |
Alicic RZ, Johnson EJ, Tuttle KR. SGLT2 inhibition for the prevention and treatment of diabetic kidney disease: a review [J]. Am J Kidney Dis, 2018, 72(2): 267-277.
|
| [4] |
Chung S, Kim GH. Use of anti-diabetic agents in non-diabetic kidney disease: from bench to bedside [J]. Life (Basel), 2021, 11(5): 389.
|
| [5] |
Wheeler DC, Toto RD, Stefánsson BV, et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy [J]. Kidney Int, 2021, 100(1): 215-224.
|
| [6] |
Boeckhaus J, Gross O. Sodium-glucose cotransporter-2 inhibitors in patients with hereditary podocytopathies, Alport syndrome, and FSGS: a case series to better plan a large-scale study [J]. Cells, 2021, 10(7): 1815.
|
| [7] |
Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes [J]. N Engl J Med, 2016, 375(4): 323-334.
|
| [8] |
Perkovic V, De Zeeuw D, Mahaffey KW, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS program randomised clinical trials [J]. Lancet Diabetes Endocrinol, 2018, 6(9): 691-704.
|
| [9] |
Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes [J]. N Engl J Med, 2019, 380(4): 347-357.
|
| [10] |
Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials [J]. Lancet, 2019, 393(10166): 31-39.
|
| [11] |
Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy [J]. N Engl J Med, 2019, 380(24): 2295-2306.
|
| [12] |
Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease [J]. N Engl J Med, 2020, 383(15): 1436-1446.
|
| [13] |
Herrington WG, Preiss D, Haynes R, et al. The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study [J]. Clin Kidney J, 2018, 11(6): 749-761.
|
| [14] |
Kobayashi K, Toyoda M, Hatori N, et al. Retrospective analysis of the renoprotective effects of long-term use of six types of sodium-glucose cotransporter 2 inhibitors in Japanese patients with type 2 diabetes mellitus and chronic kidney disease [J]. Diabetes Technol Ther, 2021, 23(2): 110-119.
|
| [15] |
Wan N, Rahman A, Hitomi H, et al. The effects of sodium-glucose cotransporter 2 inhibitors on sympathetic nervous activity [J]. Front Endocrinol, 2018, 9: 421.
|
| [16] |
Packer M. Role of impaired nutrient and oxygen deprivation signaling and deficient autophagic flux in diabetic CKD development: implications for understanding the effects of sodium-glucose cotransporter 2-inhibitors [J]. J Am Soc Nephrol, 2020, 31(5): 907-919.
|
| [17] |
Heerspink HJL, Perco P, Mulder S, et al. Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease [J]. Diabetologia, 2019, 62(7): 1154-1166.
|
| [18] |
Hussain M, Elahi A, Hussain A, et al. Sodium-glucose cotransporter-2 (SGLT-2) attenuates serum uric acid (SUA) level in patients with type 2 diabetes [J]. J Diabetes Res, 2021, 2021: 9973862.
|
| [19] |
Herat LY, Magno AL, Rudnicka C, et al. SGLT2 inhibitor-induced sympathoinhibition: a novel mechanism for cardiorenal protection [J]. JACC Basic Transl Sci, 2020, 5(2): 169-179.
|
| [20] |
Kaushal GP, Chandrashekar K, Juncos LA. Molecular interactions between reactive oxygen species and autophagy in kidney disease [J]. Int J Mol Sci, 2019, 20(15): 3791.
|
| [21] |
Terami N, Ogawa D, Tachibana H, et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice [J]. PLoS One, 2014, 9(6): e100777.
|
| [22] |
Udwan K, Abed A, Roth I, et al. Dietary sodium induces a redistribution of the tubular metabolic workload [J]. J Physiol, 2017, 595(22): 6905-6922.
|
| [23] |
Huang DY, Gao H, Boini KM, et al. In vivo stimulation of AMP-activated protein kinase enhanced tubuloglomerular feedback but reduced tubular sodium transport during high dietary NaCl intake [J]. Pflugers Arch, 2010, 460(1): 187-196.
|
| [24] |
Uthman L, Homayr A, Juni RP, et al. Empagliflozin and dapagliflozin reduce ROS generation and restore NO bioavailability in tumor necrosis factor α-stimulated human coronary arterial endothelial cells [J]. Cell Physiol Biochem, 2019, 53(5): 865-886.
|
| [25] |
Li L, Yang C, Zhao Y, et al. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease? A systematic review and meta-analysis based on observational cohort studies [J]. BMC Nephrol, 2014, 15: 122.
|
| [26] |
Chino Y, Samukawa Y, Sakai S, et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria [J]. Biopharm Drug Dispos, 2014, 35(7): 391-404.
|
| [27] |
郑淑芬，钟诗龙. SGLT2抑制剂不良反应信号的挖掘与评价[J]. 中国药房，2021, 32(8): 986-990.
|
| [28] |
Heerspink HJL, Oshima M, Zhang H, et al. Canagliflozin and kidney-related adverse events in type 2 diabetes and CKD: findings from the randomized CREDENCE trial [J]. Am J Kidney Dis, 2021, Epub ahead of print.
|
| [29] |
王翔宇，张倩，薛耀明. SGLT2抑制剂与肾脏安全性[J]. 中国实用内科杂志，2020, 40(8): 634-637.
|
| [30] |
Ye Y, Zhao C, Liang J, et al. Effect of sodium-glucose co-transporter 2 inhibitors on bone metabolism and fracture risk [J]. Front Pharmacol, 2018, 9: 1517.
|
| [31] |
Tang H, Dai Q, Shi W, et al. SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials [J]. Diabetologia, 2017, 60(10): 1862-1872.
|
| [32] |
Fitchett D. A safety update on sodium glucose co-transporter 2 inhibitors [J]. Diabetes Obes Metab, 2019, 21(Suppl 2): 34-42.
|